Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 3,386 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Pathologies Clear all

Conditions: Obesity, Diabetes Mellitus, Pre Diabetes
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: NAFLD
Interventions: NAFLD-specific weight loss intervention, Wait-list control; Behavioral · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Emergence Agitation, Pain
Interventions: IV acetaminophen, Fentanyl, PO acetaminophen; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 24 Months to 7 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
Interventions: INV-1120, Pembrolizumab; Drug · Combination Product
Lead sponsor: Shenzhen Ionova Life Sciences Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Lafayette, Indiana • San Antonio, Texas

Conditions: Chronic Pain
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 359 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Chronic Lymphocytic Leukemia
Interventions: CD3/CD28 Activated T cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neoplasm
Interventions: PF-05212384 (gedatolisib), Docetaxel, Cisplatin, Dacomitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more

Conditions: Osteopenia, Osteoporosis, Osteonecrosis
Interventions: LLP2A-ALENDRONATE, Placebo; Drug
Lead sponsor: Nancy E. Lane, MD; Other
Eligibility: 20 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Cypress, California • Walnut Creek, California • Duncansville, Pennsylvania + 1 more

Conditions: Children With Medical Complexity (CMC), Multiple Chronic Conditions, Neuromuscular Scoliosis, Shared Decision Making, Decision Support Systems, Clinical, Decision Aids
Interventions: Decision support tool; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 8 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Salt Lake City, Utah

Conditions: Muscle Spasticity, Hypertonia, Muscle, Cerebral Palsy, Multiple Sclerosis, Stroke, Hereditary Spastic Paraplegia, Dystonia, Spinal Cord Injuries
Interventions: MTR-601; Drug
Lead sponsor: Motric Bio; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2, Multiple Chronic Conditions
Interventions: CI-PVP (context-informed pre-visit planning), Standard PVP (pre-visit planning); Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cow's Milk Protein Allergy, Eosinophilic Gastrointestinal Disorders, Malabsorption/Maldigestion, Short Bowel Syndrome, Multiple Food Allergies
Interventions: Free amino acid infant formula; Other
Lead sponsor: Société des Produits Nestlé (SPN); Industry
Eligibility: 1 Day to 12 Months
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 29
States / cities: Lakeside, Arizona • Phoenix, Arizona • Tucson, Arizona + 26 more

Conditions: ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell Cancer, Recurrent, Clear Cell Renal Cell Cancer (ccRCC)
Interventions: 177Lu-TLX250; Drug
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Duarte, California • San Diego, California • Miami, Florida + 5 more

Conditions: Back Pain
Interventions: HF10 Therapy, CMM; Device · Other
Lead sponsor: Nevro Corp; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Multiple Myeloma
Interventions: BT062; Drug
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Atlanta, Georgia • Boston, Massachusetts • Buffalo, New York + 1 more

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: BI 836826, Ibrutinib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Duarte, California • Boston, Massachusetts • Portland, Oregon

Conditions: Lymphoma, Non-Hodgkin
Interventions: GSK5926371; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Iowa City, Iowa • New York, New York • Canton, Ohio

Conditions: Smith-Lemli-Opitz Syndrome
Interventions: diet; Behavioral
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Down Syndrome, Amyloid Beta-protein
Interventions: Florbetaben (BAY94-9172); Drug
Lead sponsor: Lantheus Biosciences Ltd.; Industry
Eligibility: 21 Years and older
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Sun City, Arizona • New Haven, Connecticut

Conditions: Central Nervous System Disease, Multiple Sclerosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 99 Years
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: AML, Adult, MDS, Relapse/Recurrence, Refractory Acute Myeloid Leukemia
Interventions: BST-236; Drug
Lead sponsor: BioSight Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Shreveport, Louisiana • Houston, Texas • Charlottesville, Virginia + 1 more

Conditions: Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
Interventions: Single-Dose Antibiotic, Multi-Dose Antibiotic; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Coronary Artery Diseases, Chest Pain
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Dyslipidemia
Interventions: Rimonabant (SR141716); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,033 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 28
States / cities: Mesa, Arizona • Tucson, Arizona • Irvine, California + 25 more

Search by objective public record fields.

Inflammation, Diabetes, Ethnicity and Obesity Cohort

A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men

Emergence Agitation and Pain Scores in Pediatrics When Comparing Single-modal vs Multi-modal Analgesia for ENT Surgery

An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Pain, Psychiatric Disorders, and Disability Among Veterans With and Without Polytrauma

Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids

Developing an Innovative Decision Support Tool for Pediatric Neuromuscular Scoliosis

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

Diabetes Communication and Treatment Burden

A Study to Monitor the Use of an Amino Acid-Based Infant Formula

Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC

Comparison of HF10 Therapy Combined With CMM to CMM Alone in the Treatment of Non-Surgical Refractory Back Pain

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

Phase II Study of Dietary Cholesterol for Smith-Lemli-Opitz Syndrome

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System

Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS

Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

Cardiac SPECT With Rotating Slant Hole Collimator

Obese Patients With Untreated Dyslipidemias